Lantern Pharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Lantern Pharma Inc. (LTRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 228.07 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 228.07K shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 83.30K shares, a 362.78% increase year-over-year.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 18.00K shares, a 55.00% decline year-over-year.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 88.30K shares, a 65.91% decline from fiscal 2024.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 259.00K shares, a 105.56% increase from fiscal 2023.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 126.00K shares, a 35.78% decline from fiscal 2022.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 196.20K shares, a 77.56% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 228.07K shares 10-Q · filed 2026-08-14 | 311.37K shares derived: sum of 3 quarters · filed 2026-08-14 | |
| 2026-03-31 | 228.07K shares 10-Q · filed 2026-05-15 | 311.37K shares derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2025-12-31 | 83.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 88.30K shares 10-K · filed 2026-03-30 | ||
| 2025-09-30 | 5.00K shares 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | 18.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 239.00K shares derived: sum of 2 quarters · filed 2026-03-30 | 239.00K shares derived: sum of 3 quarters · filed 2026-03-30 | 259.00K shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 221.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 221.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 241.00K shares 10-Q · filed 2024-11-07 | 281.00K shares derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 20.00K shares 10-Q · filed 2024-08-08 | 60.00K shares derived: sum of 3 quarters · filed 2025-03-27 | 76.00K shares derived: sum of 4 quarters · filed 2025-03-27 |
| 2024-03-31 | 20.00K shares 10-Q · filed 2024-05-09 | 60.00K shares derived: sum of 2 quarters · filed 2025-03-27 | 76.00K shares derived: sum of 3 quarters · filed 2025-03-27 | 76.00K shares derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | 40.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 56.00K shares derived: sum of 2 quarters · filed 2025-03-27 | 56.00K shares derived: sum of 3 quarters · filed 2025-03-27 | 126.00K shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 16.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 16.00K shares derived: sum of 2 quarters · filed 2023-11-08 | 86.00K shares 10-Q · filed 2023-11-08 | 127.20K shares derived: sum of 4 quarters · filed 2024-03-18 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 70.00K shares 10-Q · filed 2023-08-09 | 111.20K shares derived: sum of 3 quarters · filed 2024-03-18 | 211.20K shares derived: sum of 4 quarters · filed 2024-03-18 |
| 2023-03-31 | 70.00K shares 10-Q · filed 2023-05-09 | 111.20K shares derived: sum of 2 quarters · filed 2024-03-18 | 211.20K shares derived: sum of 3 quarters · filed 2024-03-18 | |
| 2022-12-31 | 41.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | 141.20K shares derived: sum of 2 quarters · filed 2024-03-18 | 196.20K shares 10-K · filed 2024-03-18 | |
| 2022-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 155.00K shares 10-Q · filed 2022-11-07 | ||
| 2022-06-30 | 55.00K shares 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | 110.50K shares 10-K · filed 2023-03-20 | |||
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | 321.74K shares 10-K · filed 2022-03-10 | |||
| 2019-12-31 | 1.34K shares 10-K · filed 2021-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |